ΔfosB induction in prefrontal cortex by antipsychotic drugs is associated with negative behavioral outcomes

Neuropsychopharmacology

Volumn 39, Issue 3, 2014, Pages 538-544

  Dietz, David M ^a,b   Kennedy, Pamela J ^a   Sun, Haosheng ^a   Maze, Ian ^c   Gancarz, Amy M ^b   Vialou, Vincent ^a   Koo, Ja Wook ^a   Mouzon, Ezekiell ^a   Ghose, Subroto ^d   Tamminga, Carol A ^d   Nestler, Eric J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

amphetamine; G9a; haloperidol; inhibitory avoidance; MK801; prepulse inhibition; transcription factors

Indexed keywords

DIZOCILPINE; HALOPERIDOL; NEUROLEPTIC AGENT; TRANSCRIPTION FACTOR DELTA FOSB;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PASSIVE AVOIDANCE TEST; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA; STARTLE REFLEX;

ADULT; AGED; ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; GENE EXPRESSION REGULATION; HALOPERIDOL; HUMANS; INHIBITION (PSYCHOLOGY); MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; MOTOR ACTIVITY; PREFRONTAL CORTEX; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; STARTLE REACTION;

EID: 84892677873     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.255     Document Type: Article

References (40)

1. Ang E, Chen J, Zagouras P, Magna H, Holland J, Schaeffer E et al (2001). Induction of nuclear factor-kB in nucleus accumbens by chronic cocaine administration. J Neurochem 79: 221-224.
2. Arguello AA, Ye X, Bozdagi O, Pollonini G, Tronel S, Bambah-Mukku D et al (2013). CCAAT enhancer binding protein D Plays an essential role in memory consolidation and reconsolidation. J Neurosci 33: 3646-3658.
3. Arguello PA, Gogos JA (2006). Modeling madness in mice: one piece at a time. Neuron 52: 179-196.
4. Atkins JB, Chlan-Fourney J, Nye HE, Hiroi N, Carlezon WA, Nestler EJ (1999). Region-specific induction of DFosB by repeated administration of typical versus atypical antipsychotic drugs. Synapse 33: 118-128.
5. Beerpoot LJ, Lipska BK, Weinberger DR (1996). Neurobiology of treatment-resistant schizophrenia: new insights and new models. Eu Neuropsychopharmacol 6(Suppl 2): S27-S34.
6. Bowers ME, Choi DC, Ressler KJ (2012). Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y. Physiol Behavior 107: 699-710.
7. Cantor-Graae E (2007). The contribution of social factors to the development of schizophrenia: a review of recent findings. Can J Psychiatry 52: 277-286.
8. Christoffel DJ, Golden SA, Heshmati M, Graham A, Birnbaum S, Neve RL et al (2012). Effects of inhibitor of [kappa]B kinase activity in the nucleus accumbens on emotional behavior. Neuropsychopharmacology 37: 2615-2623.
9. Conley RR, Kelly DL (2001). Management of treatment resistance in schizophrenia. Biol Psychiatry 50: 898-911.
10. Hill SK, Bishop JR, Palumbo D, Sweeney JA (2009). Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother 10: 43-57.
11. Hiroi N, Graybiel AM (1996). Atypical and typical neuroleptic treatments induce distinct programs of transcription factor expression in the striatum. J Comp Neurol 374: 70-83.
12. Hyman SE, Nestler EJ (1996). Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 153: 151-162.
13. Kontkanen O, Törönen P, Lakso M, Wong G, Castrén E (2002). Antipsychotic drug treatment induces differential gene expression in the rat cortex. J Neurochem 83: 1043-1053.
14. Lader M (1993). Neuroleptic-induced deficit syndrome: old problem, new challenge. J Psychopharmacol (Oxford, England) 7: 392-393.
15. Lader M (1994). Neuroleptic-induced deficit syndrome. Historical introduction. Acta Psychiatr Scand Suppl 380: 6-7.
16. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl JMed 353: 1209-1223.
17. Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA et al (2011). Advancing drug discovery for schizophrenia. Ann N Y Acad Sci 1236: 30-43.
18. Maze I, Covington HE, Dietz DM, LaPlant Q, Renthal W, Russo SJ et al (2010). Essential role of the histone methyltransferase g9a in cocaine-induced plasticity. Science 327: 213-216.
19. Maze I, Feng J, Wilkinson MB, Sun H, Shen L, Nestler EJ (2011). Cocaine dynamically regulates heterochromatin and repetitive element unsilencing in nucleus accumbens. Proc Natl Acad Sci USA 108: 3035-3040.
20. McClung CA, Nestler EJ (2003). Regulation of gene expression and cocaine reward by CREB and DeltaFosB. Nature Neurosci 6: 1208-1215.
21. Mead A, Li M, Kapur S (2008). Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two conditioned fear paradigms: contrast with haloperidol and chlordiazepoxide. Pharmacol Biochem Behav 90: 551-562.
22. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA (2012). Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17: 1206-1227.
23. Moreno J, Sealfon S, González-Maeso J (2009). Group II metabotropic glutamate receptors and schizophrenia. Cell Mol Life Sci 66: 3777-3785.
24. Nestler EJ (2008). Transcriptional mechanisms of addiction: role of deltaFosB. Philos Trans R Soc London B Biol Sci 363: 3245-3255.
25. Nestler EJ, Hyman SE (2010). Animal models of neuropsychiatric disorders. Nature Neurosci 13: 1161-1169.
26. Nestler EJ, Kelz MB, Chen JS (1999). DFosB: A molecular mediator of long-term neural and behavioral plasticity. Brain Res 835: 10-17.
27. O'Donnell P (2012). Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia. Eur J Neurosci 35: 1866-1870.
28. Park CH, Park TW, Yang JC, Lee KH, Huang GB, Tong Z et al (2012). No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial. Int Clin Psychopharmacol 27: 114-120.
29. Paxinos G, Franklin K (2003). The Mouse Brain in Stereotaxic Coordinates. Elsevier Publisher: London, UK.
30. Paxinos G, Watson C (2009). The Rat Brain in Stereotaxic Coordinates. Elsevier Publisher: London, UK.
31. Perrotti LI, Bolaños CA, Choi K-H, Russo SJ, Edwards S, Ulery PG et al (2005). DFosB accumulates in a GABAergic cell population in the posterior tail of the ventral tegmental area after psychostimulant treatment. Eur J Neurosci 21: 2817-2824.
32. Renthal W, Carle TL, Maze I, Covington HE, Truong H-T, Alibhai I et al (2008). DFosB Mediates epigenetic desensitization of the c-fos gene after chronic amphetamine exposure. J Neuroscience 28: 7344-7349.
33. Savonenko AV, Melnikova T, Laird FM, Stewart K-A, Price DL, Wong PC (2008). Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci USA 105: 5585-5590.
34. Sawa A, Snyder SH (2002). Schizophrenia: diverse approaches to a complex disease. Science 296: 692-695.
35. Seedat S, Fritelli V, Oosthuizen P, Emsley RA, Stein DJ (2007). Measuring anxiety in patients with schizophrenia. J Nerv Ment Dis 195: 320-324.
36. Selten J-P, Cantor-Graae E (2005). Social defeat: risk factor for schizophrenia? Br J Psychiatry 187: 101-102.
37. Stan AD, Ghose S, Gao XM, Roberts RC, Lewis-Amezcua K, Hatanpaa KJ et al (2006). Human postmortem tissue: what quality markers matter? Brain Res 1123: 1-11.
38. Sun H, Maze I, Dietz DM, Scobie KN, Kennedy PJ, Damez-Werno D et al (2012). Morphine epigenomically regulates behavior through alterations in histone H3 lysine 9 dimethylation in the nucleus accumbens. J Neurosci 32: 17454-17464.
39. Suzuki T, Remington G, Mulsant BH, Uchida H, Rajji TK, Graff-Guerrero A et al (2012). Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation. Psychiatry Res 197: 1-6.
40. Vialou V, Bagot RC, Ferguson D, Feng J, Ku SM, Nestler EJ (2012). Role of deltaFosB in the prefrontal cortex in CCK responses and vulnerability to stress. Neuroscience Meeting Planner New Orleans, LA: Society for Neuroscience 2012.